Disclosure Plus

YUNGJIN PHARM Expands Scope of 'KL1333' Technology Export for the First Time in 9 Years… Additional Transfer of Japanese Licensing Rights

KIM SAE-MI
2026-11-05 14:00:04
[Edaily Reporter KIM SAE-MI ] YUNGJIN PHARM(003520)has expanded the scope of its technology export for “KL1333,” a candidate drug for treating mitochondrial diseases, for the first time in 9 years and 6 months.

YUNGJIN PHARM logo (Photo courtesy of YUNGJIN PHARM)

YUNGJIN PHARM announced on the 5th that it had signed a supplemental agreement with Pharming Technologies B.V. of the Netherlands to transfer additional Japanese rights for KL1333 and expand the scope of technology use.

Under this agreement, the global rights to KL1333 secured by Pharming have been expanded from “worldwide excluding Korea and Japan” to “worldwide excluding Korea.” YUNGJIN PHARM is set to receive an additional upfront payment, milestone payments, and royalties following the transfer of the Japanese rights. Specific amounts and payment terms were not disclosed due to a confidentiality agreement.

Previously, in April 2017, YUNGJIN PHARM licensed KL1333 to Sweden-based NeuroVive Pharmaceutical AB for a total of $57 million (approximately 64.9 billion won at the exchange rate at the time). The upfront payment was $3 million (3.4 billion won), with milestone payments totaling up to $54 million (61.5 billion won), and royalties are separate. The additional revenue from this transfer of Japanese rights is not included in the original contract amount.

Subsequently, the status of the contracting party was transferred from Abliva AB to Farming. In this supplemental agreement, along with the additional transfer of Japanese rights, the scope of technology use for KL1333 was expanded to include pharmaceutically acceptable salts, prodrugs, stereoisomers, and hydrates.

The contract term is also scheduled to be extended from the original December 31, 2039, to May 19, 2047. However, this extension will take effect only after the relevant use patents are registered in individual countries.

An official from YUNGJIN PHARM stated, “To maintain business confidentiality, we have decided to withhold disclosure of the specific terms regarding the upfront payment, milestones, and royalties for the Japanese rights under this supplementary agreement until May 19, 2047.”

Economy

Corporation

IT·Science

Economy

Money Flows into AI Side Effects… Investment in Verified Startups Booms in Europe

As the spread of fraud and misinformation using artificial intelligence (AI) continues to rise, investment is flowing into European startups that verify AI-generated content. The scope of investment i…
2026-11-20 18:25:06

Corporation

Curocell Inc.’s “Limcato” to Be Covered by National Health Insurance Starting in December… Price Per Dose: 280 Million Won

“Limcato,” developed by Curocell Inc. and Korea’s first domestically produced chimeric antigen receptor T-cell (CAR-T) therapy, is set to be covered by the National Health Insurance. This is expected …
2026-11-20 17:18:01

IT·Science

CJ ENM CO., Ltd. Files for Preliminary Injunction to Halt LG HelloVision Channel Broadcasts… “We Will Protect Viewers’ Right to Choose”

CJ ENM CO., Ltd.(035760)has filed a petition for a preliminary injunction with the court, asking it to prevent LG HelloVision(037560)from suspending broadcasts on its four channels. (Photo: CJ ENM …
2026-11-20 17:17:14